Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$1.66
+4.7%
$1.48
$0.85
$2.73
$513.86M2.46.70 million shs2.60 million shs
Revvity Inc. stock logo
RVTY
Revvity
$98.68
+6.9%
$90.23
$81.22
$118.30
$11.03B1.051.26 million shs590,054 shs
Bio-Techne Corp stock logo
TECH
Bio-Techne
$48.12
-15.1%
$54.70
$46.05
$72.16
$7.53B1.412.33 million shs3.00 million shs
10x Genomics stock logo
TXG
10x Genomics
$22.76
+3.4%
$21.38
$7.72
$26.44
$2.93B2.052.56 million shs611,029 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-1.25%0.00%+17.91%-18.97%+42.34%
Revvity Inc. stock logo
RVTY
Revvity
+6.41%+8.31%+3.59%-10.89%-0.62%
Bio-Techne Corp stock logo
TECH
Bio-Techne
+3.02%+5.92%+6.68%-17.46%+13.82%
10x Genomics stock logo
TXG
10x Genomics
-1.87%+2.99%-1.43%+15.48%+155.63%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$1.66
+4.7%
$1.48
$0.85
$2.73
$513.86M2.46.70 million shs2.60 million shs
Revvity Inc. stock logo
RVTY
Revvity
$98.68
+6.9%
$90.23
$81.22
$118.30
$11.03B1.051.26 million shs590,054 shs
Bio-Techne Corp stock logo
TECH
Bio-Techne
$48.12
-15.1%
$54.70
$46.05
$72.16
$7.53B1.412.33 million shs3.00 million shs
10x Genomics stock logo
TXG
10x Genomics
$22.76
+3.4%
$21.38
$7.72
$26.44
$2.93B2.052.56 million shs611,029 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-1.25%0.00%+17.91%-18.97%+42.34%
Revvity Inc. stock logo
RVTY
Revvity
+6.41%+8.31%+3.59%-10.89%-0.62%
Bio-Techne Corp stock logo
TECH
Bio-Techne
+3.02%+5.92%+6.68%-17.46%+13.82%
10x Genomics stock logo
TXG
10x Genomics
-1.87%+2.99%-1.43%+15.48%+155.63%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
1.80
Reduce$1.670.70% Upside
Revvity Inc. stock logo
RVTY
Revvity
2.15
Hold$107.739.17% Upside
Bio-Techne Corp stock logo
TECH
Bio-Techne
2.71
Moderate Buy$72.7751.23% Upside
10x Genomics stock logo
TXG
10x Genomics
2.29
Hold$20.82-8.52% Downside

Current Analyst Ratings Breakdown

Latest TXG, PACB, TECH, and RVTY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2026
Revvity Inc. stock logo
RVTY
Revvity
Set Price Target$100.00
5/6/2026
Revvity Inc. stock logo
RVTY
Revvity
Set Price Target$117.00
5/4/2026
Revvity Inc. stock logo
RVTY
Revvity
Lower Price TargetOutperform$129.00 ➝ $125.00
4/21/2026
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Reiterated RatingSell (E+)
4/20/2026
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
DowngradeStrong-BuyHold
4/20/2026
10x Genomics stock logo
TXG
10x Genomics
Boost Price TargetBuy$22.00 ➝ $32.00
4/20/2026
10x Genomics stock logo
TXG
10x Genomics
Boost Price TargetNeutral$21.00 ➝ $30.00
4/17/2026
10x Genomics stock logo
TXG
10x Genomics
UpgradeHoldStrong-Buy
4/14/2026
10x Genomics stock logo
TXG
10x Genomics
Boost Price TargetOverweight$22.00 ➝ $30.00
4/14/2026
Revvity Inc. stock logo
RVTY
Revvity
Reiterated RatingOverweightEqual Weight$118.00 ➝ $95.00
4/14/2026
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Lower Price TargetUnderweight$1.50 ➝ $1.00
(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$160.01M3.21$0.84 per share1.96$0.02 per share82.75
Revvity Inc. stock logo
RVTY
Revvity
$2.86B3.86$10.06 per share9.81$63.95 per share1.54
Bio-Techne Corp stock logo
TECH
Bio-Techne
$1.22B6.17$2.15 per share22.39$12.24 per share3.93
10x Genomics stock logo
TXG
10x Genomics
$642.82M4.52N/AN/A$6.24 per share3.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$546.38M-$1.84N/AN/AN/A-341.47%-326.43%-19.40%5/7/2026 (Estimated)
Revvity Inc. stock logo
RVTY
Revvity
$241.20M$2.0847.4316.471.848.45%7.92%4.81%N/A
Bio-Techne Corp stock logo
TECH
Bio-Techne
$73.40M$0.5194.4025.323.606.67%13.94%10.76%5/6/2026 (Estimated)
10x Genomics stock logo
TXG
10x Genomics
-$43.54M-$0.35N/AN/AN/A-6.77%-6.89%-5.34%5/7/2026 (Estimated)

Latest TXG, PACB, TECH, and RVTY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$0.17N/AN/AN/A$39.95 millionN/A
5/7/2026Q1 2026
10x Genomics stock logo
TXG
10x Genomics
-$0.27N/AN/AN/A$146.38 millionN/A
5/6/2026Q3 2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.55$0.53-$0.02$0.32$316.08 million$311.42 million
5/5/2026Q1 2026
Revvity Inc. stock logo
RVTY
Revvity
$1.02$1.06+$0.04$0.36$704.07 million$711.12 million
2/12/2026Q4 2025
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$0.19-$0.12+$0.07-$0.13$44.60 million$44.65 million
2/12/2026Q4 2025
10x Genomics stock logo
TXG
10x Genomics
-$0.19-$0.13+$0.06-$0.13$160.35 million$166.03 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/AN/AN/AN/AN/A
Revvity Inc. stock logo
RVTY
Revvity
$0.280.28%N/A13.46%N/A
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.320.67%N/A62.75%N/A
10x Genomics stock logo
TXG
10x Genomics
N/AN/AN/AN/AN/A

Latest TXG, PACB, TECH, and RVTY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/30/2026
Revvity Inc. stock logo
RVTY
Revvity
quarterly$0.070.32%7/17/20267/17/20268/7/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
120.65
5.15
4.47
Revvity Inc. stock logo
RVTY
Revvity
0.36
1.68
1.40
Bio-Techne Corp stock logo
TECH
Bio-Techne
0.13
4.54
3.08
10x Genomics stock logo
TXG
10x Genomics
N/A
4.46
4.09

Institutional Ownership

CompanyInstitutional Ownership
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/A
Revvity Inc. stock logo
RVTY
Revvity
86.65%
Bio-Techne Corp stock logo
TECH
Bio-Techne
98.95%
10x Genomics stock logo
TXG
10x Genomics
84.68%

Insider Ownership

CompanyInsider Ownership
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
2.40%
Revvity Inc. stock logo
RVTY
Revvity
0.85%
Bio-Techne Corp stock logo
TECH
Bio-Techne
1.30%
10x Genomics stock logo
TXG
10x Genomics
8.84%
CompanyEmployeesShares OutstandingFree FloatOptionable
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
730310.49 million303.04 millionOptionable
Revvity Inc. stock logo
RVTY
Revvity
11,000111.80 million110.85 millionOptionable
Bio-Techne Corp stock logo
TECH
Bio-Techne
3,100156.45 million154.42 millionOptionable
10x Genomics stock logo
TXG
10x Genomics
1,240127.75 million116.46 millionOptionable

Recent News About These Companies

10x Genomics (NASDAQ:TXG) CEO Sells $122,800.00 in Stock

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Pacific Biosciences of California stock logo

Pacific Biosciences of California NASDAQ:PACB

$1.66 +0.08 (+4.75%)
As of 12:01 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Revvity stock logo

Revvity NYSE:RVTY

$98.68 +6.38 (+6.91%)
As of 12:01 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Bio-Techne stock logo

Bio-Techne NASDAQ:TECH

$48.12 -8.56 (-15.11%)
As of 12:01 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

10x Genomics stock logo

10x Genomics NASDAQ:TXG

$22.76 +0.75 (+3.41%)
As of 12:01 PM Eastern
This is a fair market value price provided by Massive. Learn more.

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.